HER-Vaxx is going to take a lot longer than two years, if we're talking about reaching market. That estimate is under the condition that our drug will eventually show results profound enough to interest the FDA in speeding up the pace to market. But even then I would expect another 4-5 years as the FDA would really only shave a year off.
Unfortunately for us, the "21st Century Cures Act" in the U.S. and the "Accelerated Approval Pathways" developed in Japan are for innovative regenerative medicine's only (which obviously we are not).
I only care about extracting max value out of our tech/platform, with a deal or two along the way. Which I believe is only a year or two away.
Add to My Watchlist
What is My Watchlist?
